{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:06:01Z","timestamp":1791165961499,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Actinic keratoses (AKs) are skin lesions resulting from sun exposure and carry a risk of developing into squamous cell carcinoma. Current therapies for AK eradication include topical 5-fluorouracil (5-FU) and photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA). However, sequential therapy with 5-FU-ALA-PDT may offer improved outcome compared to ALA-PDT alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>The purpose of this study is to compare the long-term efficacy of AK clearance by sequential therapy with 5-FU-ALA-PDT versus ALA-PDT alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>This is a single center, randomized split-site approach study on equivalent anatomical and clinical sites. Seventeen patients were enrolled with one half of the site randomized to receive sequential 5-FU-ALA-PDT and the other side with ALA-PDT monotherapy. Total AKs were counted at baseline, 6 and 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Median percentage reduction in AK number at 6 months for 5-FU-ALA-PDT versus ALA-PDT was 100% for 5-FU-ALA-PDT (N = 21) and 66.7% for ALA-PDT (N = 21), <jats:italic toggle=\"yes\">p<\/jats:italic> = .001. Median percentage reduction in AK number at 12 months for 5-FU-ALA-PDT versus ALA-PDT was 100% for 5-FU-ALA-PDT (N = 22) and 82.6% for ALA-PDT (N = 22), <jats:italic toggle=\"yes\">p<\/jats:italic> = .0002.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Sequential therapy with 5-FU-ALA-PDT is more effective at AK clearance at 6 and 12 months compared to ALA-PDT monotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001161","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T18:11:42Z","timestamp":1495908702000},"page":"1170-1175","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy"],"prefix":"10.1097","volume":"43","author":[{"given":"Susan","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Wisconsin, Madison, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edidiong C.N.","family":"Kaminska","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Pritzker School of Medicine, The University of Chicago, NorthShore University Health System, Skokie, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Tsoukas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1684\/ejd.2009.0706","article-title":"Predisposing factors of actinic keratosis in a North-West German population","volume":"19","author":"Hensen","year":"2009","journal-title":"Eur J Dermatol"},{"key":"R2-20230814","first-page":"462","article-title":"New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma)","volume":"4","author":"Cockerell","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archdermatol.2009.378","article-title":"Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression","volume":"146","author":"Padilla","year":"2010","journal-title":"Arch Dermatol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1172\/JCI57415","article-title":"From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma","volume":"122","author":"Ratushny","year":"2012","journal-title":"J Clin Invest"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"Marks","year":"1988","journal-title":"Lancet"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical Tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamadermatol.2014.1253","article-title":"Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis","volume":"150","author":"Patel","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.clindermatol.2013.05.007","article-title":"Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies","volume":"31","author":"Schmitt","year":"2013","journal-title":"Clin Dermatol"},{"key":"R10-20230814","first-page":"28","article-title":"Actinic keratosis: update on field therapy","volume":"7","author":"Goldenberg","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R11-20230814","first-page":"9","article-title":"Treatment options in the management of actinic keratosis","volume":"74","author":"Jorizzo","year":"2004","journal-title":"Cutis"},{"key":"R12-20230814","first-page":"161","article-title":"Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy","volume":"4","author":"Gilbert","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"R13-20230814","first-page":"372","article-title":"Prospective, case-based assessment of sequential therapy with topical fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis","volume":"10","author":"Martin","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"R14-20230814","first-page":"54","article-title":"Combining field therapies for actinic keratoses: novel approaches that intensify photodynamic therapy","volume":"11","author":"Kaminska","year":"2013","journal-title":"Skinmed"},{"key":"R15-20230814","first-page":"33","article-title":"A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage","volume":"40","author":"Touma","year":"2004","journal-title":"Arch Dermatol"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1468-3083.2009.03259.x","article-title":"Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities","volume":"23","author":"Sotiriou","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0190-9622(99)70114-3","article-title":"A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses","volume":"41","author":"Kurwa","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1365-2133.2006.07520.x","article-title":"Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up","volume":"155","author":"Tschen","year":"2006","journal-title":"Br J Dermatol"},{"key":"R19-20230814","first-page":"35","article-title":"Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream","volume":"8","author":"Shaffelburg","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mjd.2002.119649","article-title":"Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study","volume":"47","author":"Szeimies","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/1011-1344(90)85083-9","article-title":"Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience","volume":"6","author":"Kennedy","year":"1990","journal-title":"J Photochem Photobiol B"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1997.03890420065007","article-title":"Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study","volume":"133","author":"Jeffes","year":"1997","journal-title":"Arch Dermatol"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers3022516","article-title":"Cell death pathways in photodynamic therapy of cancer","volume":"3","author":"Mroz","year":"2011","journal-title":"Cancers (Basel)"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0190-9622(81)80196-X","article-title":"Topical chemotherapy with 5-fluorouracil. A review","volume":"4","author":"Goette","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archdermatol.2009.97","article-title":"Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis","volume":"145","author":"Sachs","year":"2009","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201709000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:05:22Z","timestamp":1692039922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201709000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001161","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}